Alembic Pharma

Who are in the management team of Alembic Pharma?

As of March 2023, the management team of Alembic Pharma includes Chirayu R Amin (Chairman & CEO), Pranav Amin and Shaunak Amin (Managing Directors), Rajkumar Baheti (CFO), and Manisha Saraf (Company Secretary), along with several independent directors. They oversee the company's strategic direction and operations.

As of March 2023, the management team of Alembic Pharma includes the following individuals:<BR><BR>1. Chirayu R Amin - Chairman & CEO<BR>2. Pranav Amin - Managing Director<BR>3. Shaunak Amin - Managing Director<BR>4. Rajkumar Baheti - Director (Finance) & CFO<BR>5. Manisha Saraf - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent directors:<BR>- Pranav N Parikh<BR>- K G Ramanathan<BR>- Paresh Saraiya<BR>- Archana Hingorani<BR>- Ashok Barat<BR>- Jai S Diwanji<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.

Has Alembic Pharma declared dividend?

Yes, Alembic Pharmaceuticals Ltd. has declared a 550% dividend, amounting to ₹11 per share, with an ex-date of July 15, 2024. While recent performance shows mixed returns, the company has demonstrated positive total returns over the 2-year (81.26%) and 5-year (20.15%) periods.

Alembic Pharmaceuticals Ltd. has declared a 550% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 550%<BR>- Amount per share: 11<BR>- Ex-date: 15 Jul 24<BR><BR>Dividend Yield: 1.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.25%, with no dividend return, resulting in a total return of -9.25%.<BR><BR>Over the past year, the price return was 10.07%, with a dividend return of 1.23%, leading to a total return of 11.3%.<BR><BR>In the 2-year period, the price return was 78.15%, with a dividend return of 3.11%, culminating in a total return of 81.26%.<BR><BR>For the 3-year period, the price return was 34.58%, with a dividend return of 4.03%, resulting in a total return of 38.61%.<BR><BR>In the last 4 years, the price return was 3.58%, with a dividend return of 4.30%, giving a total return of 7.88%.<BR><BR>Over the past 5 years, the price return was 15.37%, with a dividend return of 4.78%, leading to a total return of 20.15%.<BR><BR>Overall, Alembic Pharmaceuticals has declared a significant dividend, and while the recent performance shows mixed returns, the longer-term total returns indicate a positive trend, particularly over the 2-year and 5-year periods.

Who are the peers of the Alembic Pharma?

Alembic Pharma's peers include J B Chemicals, Pfizer, ERIS Lifescience, AstraZeneca, OneSource Specialty, Concord Biotech, Neuland Labs, Jubilant Pharma, Natco Pharma, and Sai Life. Management risk varies from excellent at Concord Biotech to average at Jubilant Pharma and Sai Life, with ERIS Lifescience showing the highest 1-year return at 74.62% and Natco Pharma the lowest at -20.35%.

Peers: The peers of Alembic Pharma are J B Chemicals &, Pfizer, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., Concord Biotech, Neuland Labs., Jubilant Pharmo, Natco Pharma, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at J B Chemicals &, Pfizer, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., Alembic Pharma, Neuland Labs., Natco Pharma, and the rest. Average management risk is noted at Jubilant Pharmo and Sai Life. Growth is Excellent at OneSource Speci., Good at Concord Biotech and Natco Pharma, Average at J B Chemicals & and Neuland Labs., and Below Average at Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, and the rest. Capital Structure is Excellent at J B Chemicals &, Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, Concord Biotech, Neuland Labs., and Natco Pharma, while Average is seen at Jubilant Pharmo and Below Average at OneSource Speci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is ERIS Lifescience at 74.62%, while the lowest is Natco Pharma at -20.35%. Alembic Pharma's own 1-year return is -5.38%, which is higher than Natco Pharma's but lower than the rest. Additionally, Concord Biotech and Natco Pharma have negative six-month returns.

What does Alembic Pharma do?

Alembic Pharmaceuticals Ltd. is a large-cap company that manufactures and markets generic pharmaceutical products, primarily focusing on branded generics in India. As of March 2025, it reported net sales of ₹17,696 Cr and a net profit of ₹1,569 Cr.

Overview:<BR>Alembic Pharmaceuticals Ltd. manufactures and markets generic pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry as a large-cap company.<BR><BR>History:<BR>Incorporated on June 16, 2010, as a wholly owned subsidiary of Alembic Ltd., Alembic Pharmaceuticals has established itself as a leader in branded generics in India. The latest reported quarterly results indicate net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 17,696 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,569 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 20,257 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.07% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 11.03% <BR>Price to Book: 3.91<BR><BR>Contact Details:<BR>Address: Alembic Road, Vadodara Gujarat : 390003 <BR>Tel: 91-0265-2280550 <BR>Email: apl.investors@alembic.co.in <BR>Website: http://www.alembicpharmaceuticals.com

Who are the top shareholders of the Alembic Pharma?

The top shareholders of Alembic Pharma include Nirayu Limited with 35.64%, mutual funds holding 9.2%, foreign institutional investors at 3.94%, and DSP Midcap Fund as the largest public shareholder with 4.6%. Individual investors own 7.07% of the total shares.

The top shareholders of Alembic Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nirayu Limited, which owns 35.64% of the company. Additionally, mutual funds collectively hold 9.2% through 21 different schemes, while foreign institutional investors (FIIs) account for 3.94% with 151 FIIs involved. The highest public shareholder is DSP Midcap Fund, holding 4.6%. Individual investors also have a stake, representing 7.07% of the total shares.

How big is Alembic Pharma?

As of 24th July, Alembic Pharmaceuticals Ltd. has a market capitalization of 20,115.00 Cr, with net sales of 6,672.09 Cr and a net profit of 583.43 Cr reported in the latest four quarters. The company has shareholder's funds of 5,190.94 Cr and total assets of 7,606.90 Cr for the annual period ending in March 2025.

As of 24th July, Alembic Pharmaceuticals Ltd. has a market capitalization of 20,115.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Alembic Pharmaceuticals reported net sales of 6,672.09 Cr and a net profit of 583.43 Cr.<BR><BR>For the latest annual period ending in March 2025, the company has shareholder's funds amounting to 5,190.94 Cr and total assets of 7,606.90 Cr.

When is the next results date for Alembic Pharma?

The next results date for Alembic Pharma is 04 November 2025.

The next results date for Alembic Pharma is scheduled for 04 November 2025.

Is Alembic Pharma overvalued or undervalued?

As of November 6, 2025, Alembic Pharma is considered very attractive and undervalued compared to peers, with a PE ratio of 28.37 and a PEG ratio of 0.00, indicating strong growth potential despite recent stock performance declines.

As of 6 November 2025, Alembic Pharma's valuation grade has moved from attractive to very attractive, indicating a significant positive shift in its valuation outlook. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 28.37, an EV to EBITDA of 27.19, and a Price to Book Value of 0.34, which highlight its potential for growth relative to its market price.<BR><BR>In comparison to its peers, Alembic Pharma's valuation stands out; for instance, Sun Pharma has a PE ratio of 35.02 and Divi's Lab is at 79.09, both categorizing them as expensive. Additionally, while Alembic Pharma's PEG ratio is 0.00, indicating no growth premium, competitors like Cipla and Dr. Reddy's Labs have PEG ratios of 1.25 and 2.15, respectively, suggesting that Alembic may offer better value. Despite a recent decline in stock performance relative to the Sensex over the past year, the company's strong fundamentals and attractive valuation metrics position it favorably in the market.

How has been the historical performance of Alembic Pharma?

Alembic Pharma has shown consistent growth in net sales, reaching 6,672.08 Cr in March 2025, but profit after tax declined to 581.14 Cr. Total assets increased to 7,606.90 Cr, while cash flow from operating activities significantly dropped to 87.00 Cr, indicating potential cash management challenges.

Answer:<BR>The historical performance of Alembic Pharma shows a trend of increasing net sales and total operating income over the years, with net sales reaching 6,672.08 Cr in March 2025, up from 6,228.63 Cr in March 2024 and 5,652.62 Cr in March 2023. The total expenditure has also risen, amounting to 5,663.84 Cr in March 2025, compared to 5,295.27 Cr in March 2024. Operating profit, excluding other income, was 1,008.24 Cr in March 2025, reflecting a steady increase from 933.36 Cr in March 2024. However, profit after tax showed a slight decline to 581.14 Cr in March 2025 from 616.80 Cr in March 2024. The company's total assets increased to 7,606.90 Cr in March 2025, up from 6,275.94 Cr in March 2024, while total liabilities also rose to 7,606.90 Cr in March 2025, compared to 6,275.94 Cr in March 2024. Cash flow from operating activities decreased significantly to 87.00 Cr in March 2025 from 803.00 Cr in March 2024, indicating a shift in cash generation capabilities.<BR><BR>Breakdown:<BR>Alembic Pharma's financial performance has demonstrated a consistent growth trajectory in net sales, which increased from 5,305.79 Cr in March 2022 to 6,672.08 Cr in March 2025. This growth in sales has been accompanied by rising total operating income, which reached 6,672.08 Cr in March 2025. Despite this increase, the total expenditure also rose, leading to an operating profit of 1,008.24 Cr in March 2025, an improvement from the previous year. However, profit after tax saw a decrease to 581.14 Cr in March 2025, down from 616.80 Cr in March 2024. The company's total assets grew significantly to 7,606.90 Cr in March 2025, reflecting a robust asset base, while total liabilities increased correspondingly. The cash flow from operating activities, however, faced a notable decline, indicating potential challenges in cash management despite the overall growth in sales and assets.

Is Alembic Pharma technically bullish or bearish?

As of December 1, 2025, Alembic Pharma's technical outlook is bearish, driven by negative indicators such as a bearish MACD, moving averages, and KST, with no signs of bullish momentum from the RSI.

As of 1 December 2025, the technical trend for Alembic Pharma has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. Both Bollinger Bands and the monthly MACD are mildly bearish, indicating a continuation of negative momentum. The RSI shows no signals on both weekly and monthly time frames, suggesting a lack of bullish momentum. Overall, the technical outlook remains negative.

Are Alembic Pharmaceuticals Ltd. latest results good or bad?

Alembic Pharmaceuticals Ltd.'s latest Q3 FY26 results are considered bad, with a 28.01% drop in net profit quarter-on-quarter and a decline in profit margins, despite a 10.84% year-on-year sales growth. The company's operational challenges have led to a downgrade in its quality grade and bearish investor sentiment.

Alembic Pharmaceuticals Ltd.'s latest results for Q3 FY26 indicate a challenging period for the company. While the net sales showed a year-on-year growth of 10.84%, there was a sequential decline of 1.77% compared to the previous quarter. This suggests that although the company is generating more revenue compared to last year, it is struggling to maintain its momentum on a quarter-to-quarter basis.<BR><BR>The net profit has seen a significant drop, falling by 28.01% quarter-on-quarter and 3.94% year-on-year, which raises concerns about the company's operational efficiency. The profit after tax (PAT) margin also compressed sharply from 9.62% in the previous quarter to just 7.03%, indicating rising costs and potential issues with pricing power.<BR><BR>Overall, the results reflect operational challenges and a deteriorating financial performance, leading to a downgrade in the company's quality grade from "Excellent" to "Average." The stock has underperformed significantly, trading well below its 52-week high, and investor sentiment appears to be bearish. Given these factors, the latest results can be characterized as bad, highlighting the need for the company to address its operational issues to regain investor confidence.

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 14-May, Alembic Pharmaceuticals Ltd. is seeing a stock price increase to 786.45, up 2.35%, driven by recent gains and strong debt servicing capability. Despite past challenges, the current positive momentum and favorable sector performance are boosting investor confidence.

As of 14-May, Alembic Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 786.45, reflecting an increase of 18.05 or 2.35%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.43% today and has shown consecutive gains over the last two days, accumulating a total return of 2.84% during this period. Additionally, the stock reached an intraday high of Rs 791.2, indicating positive trading momentum.<BR><BR>The broader pharmaceutical and drugs sector has also seen gains of 2.41%, contributing to the favorable environment for Alembic Pharmaceuticals. Furthermore, the company demonstrates a strong ability to service its debt, evidenced by a low Debt to EBITDA ratio of 1.32 times, which may instill confidence among investors. The stock is trading at a discount compared to its peers' average historical valuations, and despite a negative return of -13.74% over the past year, the company's profits have increased by 11.7%, suggesting potential for recovery.<BR><BR>However, it is important to note that while the stock is currently rising, it has faced challenges in the long term, including a decline in operating profit growth over the last five years and underperformance compared to the market. Despite these concerns, the current positive performance and investor sentiment appear to be driving the stock's rise at this time.

Which are the latest news on Alembic Pharma?

Should I buy, sell or hold Alembic Pharmaceuticals Ltd.?